ASX Linkedin Twitter               

 

Our Other Oncolytic Viruses

Viralytics has investigated a range of Coxsackievirus oncolytic immunotherapeutics for cancer treatment due their targeted oncolytic activity.  Viralytics holds the intellectual property rights to 5 Coxsackieviruses including CVA13, 15, 18 and 21 (CAVATAK®) and Echovirus 1 (EVATAKTM).

EVATAK™ is an ECHOvirus – ECHO is an acronym for ‘enteric cytopathic human orphan’. Orphan was used to describe the virus as it is not linked to any human disease, and hence as oncolytic immunotherapy is not expected to result in side effects of any significance.  EVATAKTM binds specifically to the integrin α2β1 (alpha 2 beta 1) receptor. This receptor is found in high levels on ovarian, prostate and gastric cancer cells and preclinical studies have shown that  EVATAKTM destroys these cancer cells and so has the potential to be a useful therapeutic for these cancers.

While all these viruses have been assessed in preclinical studies the Coxsackievirus (CVA21) demonstrated most potential and as such became Viralytics Lead Product for clinical development.

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).